Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
$282K Hold
4,068
0.02% 482
2022
Q2
$282K Sell
4,068
-340
-8% -$25.2K 0.02% 494
2022
Q1
$339K Buy
4,408
+1,351
+44% +$97.2K 0.02% 497
2021
Q4
$234K Buy
3,057
+260
+9% +$19.1K 0.02% 607
2021
Q3
$206K Buy
+2,797
New +$210K 0.02% 637
2021
Q2
Sell
-2,737
Closed -$204K 681
2021
Q1
$204K Buy
+2,737
New +$208K 0.02% 561
2017
Q3
Sell
-35,347
Closed -$1.6M 290
2017
Q2
$1.6M Hold
35,347
0.25% 105
2017
Q1
$1.5M Hold
35,347
0.23% 104
2016
Q4
$1.42M Sell
35,347
-19
-0.1% -$733 0.25% 102
2016
Q3
$1.37M Buy
+35,366
New +$1.34M 0.25% 102

Other funds holding HOLX

Corient Capital Partners's HOLX Position: Q3 2022 in Review

Corient Capital Partners held its Hologic (HOLX) position steady in Q3 2022 at 4,068 shares worth $282K. The position accounts for 0.02% of the portfolio, ranked #482.

Corient Capital Partners first reported a position in HOLX in Q3 2016 and has held it in 10 quarters since. The position peaked at $1.6M in Q2 2017. 653 funds tracked by Wall St. Rank hold HOLX as of Q3 2022.

  • Corient Capital Partners held 4,068 shares of Hologic worth $282K as of Q3 2022.
  • Corient Capital Partners left its Hologic share count unchanged in Q3 2022.
  • Hologic made up 0.02% of Corient Capital Partners's portfolio in Q3 2022, its #482 holding.
  • Corient Capital Partners first reported a position in Hologic in Q3 2016 and has held it in 10 quarters since.
  • Corient Capital Partners's Hologic position peaked at $1.6M in Q2 2017.
  • 653 funds tracked by Wall St. Rank held Hologic as of Q3 2022.

Based on Corient Capital Partners's 13F filing for Q3 2022, filed 14 Nov 2022.